EVOLV PHARMA
EU GMP PHARMACEUTICAL MANUFACTURING
About us
Evolv is a healthcare technology company pioneering new approaches to innovative cannabinoid-based medication and technology in Europe.
OUR PEOPLE
Our team has a proven track record of growing successful large-scale businesses and is backed by an exceptional advisory team across science, clinical development and pharmaceutical commercialisation.
-
MONIQUE ELLIS
CO-FOUNDER
Read more
Results-driven, highly experienced business and technology entrepreneur. Experience in scaling global award winning teams of 500+ and the oversight of strategy, planning, operations, workflow management with and extensive process scalability. Monique is a champion of diversity, equality and inclusion and is an endometriosis patient.
-
GEORGE MEEK
CO-FOUNDER
Read more
Accomplished growth and business development executive with two decades of experience in corporate sales and operational strategy. Experience in large scale, global technology companies has allowed George to deliver successful fundraising, key partnership programs and innovative industry development.
-
NENAD CUBRINOVSKI
CO-FOUNDER
Read more
Proven track record of success in optimizing operations and driving business growth. Track record in scaling teams of +250 in highly competitive and regulated industries and has a deep understanding of the industry's challenges and opportunities.
-
RON DOWNEY
CHAIRMAN
Read more
Founder/Investor, Exec & Non-Exec Chair. Seasoned technology entrepreneur and experience leading high-growth and profitable global companies. Ron has a track record of driving innovation, scale and delivering exceptional shareholder value.
-
GWENAELLE PEMBERTON
Regulatory Advisor
Read more
Functional and highly experienced regulatory and drug delivery leader with extensive global and regional experience. Ex. VP Global Regulatory Pfizer & Gilead Life Science. Ex. Member of The Regulatory Strategy Committee at EFPIA.
-
PAUL CARTER
Commercial Advisor
Read more
Bio-Pharma Executive. Non-Exec and Advisor. Former Exec Vice President, Chief Commercial Officer at Gilead Science. Strong Bio-Pharma network worldwide.
-
BILL RINEHART
BOARD
Read more
US Cannabis & Technology Industry Executive. Multiple Successful IPOs and Exits (5x), Limelight Networks, Unicorn Media, Sunday Goods, Bold.
-
DR ANNE KATRIN SCHLAG PHD
Strategic Advisory Board
Read more
Chartered Psychologist and Head of Research at Drug Science, where she leads the research for the Medical Cannabis Working Group, and the Medical Psychedelics Working Group. Anne holds Honorary Senior Fellowships at both Imperial College London and King's College London.
-
DR CALLIE SEAMAN PHD
Strategic Advisory Board
Read more
Leading PhD Plant Scientist, a medicinal Cannabis Patient, educator, researcher and formulation specialist with numerous scientific papers and books published. Callie is Board Advisor for Medcann and PLEA and on the executive board of the Cannabis Industry Council.
-
HANNAH DEACON
Strategic Advisory Board
Read more
Executive Director at The Medical Cannabis Clinicians Society and UK Lead Campaigner for fair access to prescription medical cannabis. Hannah became the first person to legally enter the UK with a prescription to help her son in 2018.
-
DR SUNIL ARORA
Strategic Advisory Board
Read more
Chief Medical Officer and medical educator with over 16 years experience as a doctor, working as a Consultant in Anaesthetics and Pain. Sunil is one of the most experienced medical cannabis prescribers in the UK, and one of the first doctors to prescribe in 2019. Sunil is a committed patient advocate and educator to other doctors in this field, through his work with the Medical Cannabis Clinicians Society.
-
DOM DE LORENZO
Strategic Advisory Board
Read more
Co-founder and Chief Product Officer of Estii with over 20 years of experience in the tech industry. Dom has held various senior leadership roles across product management, development, design, and strategy. Dom is known for his technical expertise, product vision, and business acumen, and is passionate about creating products that solve complex problems and drive real customer value.
-
DR MIKE ARMOUR
Strategic Advisory Board
Read more
Dr Mike Armour is an Associate Professor in reproductive health at NICM Health Research Institute, Western Sydney University. Mike has published over 80 peer reviewed articles on various aspects of women's health Mike is also an author on several textbook chapters including a forthcoming chapter on the use of medicinal cannabis to treat endometriosis. Mike has had over 400 pieces of international news media with an estimated readership of 80 million across over 100 countries. He is a World Endometriosis Society Ambassador, Chair of Endometriosis Australia's clinical advisory committee, Chair of Endometriosis Australia's research committee, lead of the Menstrual Cycle Research Network (MCRN) and Chair of the Australasian Interdisciplinary Researchers in Endometriosis (AIRE).
OUR FOCUS
-
EVIDENCE-DRIVEN AND ETHICAL
Science-based formulation and technology. Harnessing digital technology to gather real world evidence to support regulatory pathway and maximise patient benefit.
-
INNOVATIVE
Evolv's therapeutic development is centered on proprietary, scientifically-formulated, precision-dosed cannabinoid prescription medicine aimed at replacing potentially harmful prescription analgesics, anti-inflammatories as well as contraceptive medication.
-
COMMITTED TO CLINICIAN EDUCATION AND PATIENT SAFETY
Providing clinicians with regulated, proprietary formulated and precision-dosing products backed by an education programme, ongoing research and strategic partnerships with patient groups in UK, Europe, Canada and Australia.
-
MINIMISING ENVIRONMENTAL AND SOCIAL IMPACT
Our solar powered facility delivers on all domains of ESG bringing jobs, operating the latest sustainable technologies and reducing risk and cost of commercial cultivation supply-chains. We integrate bio-tech and climate-tech in a highly regulated market for production, traceability and efficient use of energy and water.
Evolv's primary goal is to improve life, alleviate symptoms, and offer alternative treatment options. The development of our therapeutic compassionate patient access programme is vital to removing barriers to entry for the patients who are in most need of access.